1) Development of Theranostic Probe Our lab is focusing on developing liposome products with photodynamic therapy(PDT) effect among diverse theranostic probes. PDT is a phototherapy technique that can destruct target sites like tumor lesions by stimulating probes with light of a specific wavelength and generating reactive oxygen species(ROS) subsequently. In previous studies, PDT is conducted by using visible light to excite photosensitizer to produce ROS. But it has disadvantage of limited penetration ability through tissues. To overcome this issue, we developed a liposome nanoplatform contains photosensitizer generating ROS and Eu-DTPA emitting radioluminescence that has higher photometric intensity than visible light when excited by radioisotope. It is demonstrated that Eu-DTPA loading liposome has the excellent ability to diagnose and treat tumors within thick layers of tissue. Meanwhile, We are also developing gold loaded liposomes capable of photothermal therapy and other theranostic probes for various diseases.

2) Radiogenomics Research Our lab is conducting research using Radiogenomics data. Exploring the relationships between Radiomics and Genomics, we have identified an association between genomic and FDG PET derived tumor heterogeneity. We have also attempted utilizing single cell RNA sequencing to identify specific marker of severe COVID-19. Furthermore, we integratively analyze spatial transcriptomics data and fluorescence images of a drug to explore molecular markers that are related to accumulation and effect of the drug in tumor tissues.